Trial · NCT02850406
Results by group156
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 156
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part A: Maximum Concentration (Cmax) of Voxelotor in Whole Blood | Part A: Participants Aged 12 to 17 Years: Voxelotor 600 mg | 24300 | Geometric Coefficient of Variation 36.39 | Nanogram per milliliter | |
| Part A: Maximum Concentration (Cmax) of Voxelotor in Whole Blood | Part A: Participants Aged 6 to 11 Years: Voxelotor 600 mg | 47300 | Geometric Coefficient of Variation 43.62 | Nanogram per milliliter | |
| Part A: Area Under the Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Voxelotor in Whole Blood | Part A: Participants Aged 12 to 17 Years: Voxelotor 600 mg | 1570000 | Geometric Coefficient of Variation 38.13 | Hours*nanogram per milliliter | |
| Part A: Area Under the Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Voxelotor in Whole Blood | Part A: Participants Aged 6 to 11 Years: Voxelotor 600 mg | 2540000 | Geometric Coefficient of Variation 50.25 | Hours*nanogram per milliliter | |
| Part A: Area Under the Concentration-Time Curve (AUC) From Time 0 Extrapolated to Infinity (AUC0-inf) of Voxelotor in Whole Blood | Part A: Participants Aged 12 to 17 Years: Voxelotor 600 mg | 1520000 | Geometric Coefficient of Variation 40.98 | Hours*nanogram per milliliter | |
| Part A: Area Under the Concentration-Time Curve (AUC) From Time 0 Extrapolated to Infinity (AUC0-inf) of Voxelotor in Whole Blood | Part A: Participants Aged 6 to 11 Years: Voxelotor 600 mg | 2570000 | Geometric Coefficient of Variation 50.59 | Hours*nanogram per milliliter | |
| Part B: Change From Baseline to Week 24 in Hemoglobin Level | Part B: Voxelotor 900 mg QD | 0.7 | Standard Deviation 0.86 | Gram per deciliter | |
| Part B: Change From Baseline to Week 24 in Hemoglobin Level | Part B: Voxelotor 1500 mg QD | 0.2 | Standard Deviation 1.02 | Gram per deciliter | |
| Part C: Change From Baseline to Week 48 in Cerebral Blood Flow | Part C: Participants Aged 4 to 11 Years: Voxelotor 1500 mg QD | -0.4 | Standard Deviation 16.76 | Centimeter per second | |
| Part C: Change From Baseline to Week 48 in Cerebral Blood Flow | Part C: Participants Aged 12 to 17 Years: Voxelotor 1500 mg QD | -26.3 | Standard Deviation 11.59 | Centimeter per second | |
| Part D: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Part D: Participants Aged 6 Months to <2 Years: Voxelotor 1500 mg QD | Non-SCD related TEAEs | 9 | Participants | |
| Part D: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Part D: Participants Aged 2 to <4 Years: Voxelotor 1500 mg QD | Non-SCD related TEAEs | 20 | Participants | |
| Part D: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Part D: Participants Aged 6 Months to <2 Years: Voxelotor 1500 mg QD | Non-SCD related SAEs | 6 | Participants | |
| Part D: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Part D: Participants Aged 2 to <4 Years: Voxelotor 1500 mg QD | Non-SCD related SAEs | 12 | Participants | |
| Part D: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Part D: Participants Aged 6 Months to <2 Years: Voxelotor 1500 mg QD | SCD related TEAEs | 6 | Participants | |
| Part D: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Part D: Participants Aged 2 to <4 Years: Voxelotor 1500 mg QD | SCD related TEAEs | 14 | Participants | |
| Part D: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Part D: Participants Aged 6 Months to <2 Years: Voxelotor 1500 mg QD | SCD related SAEs | 3 | Participants | |
| Part D: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Part D: Participants Aged 2 to <4 Years: Voxelotor 1500 mg QD | SCD related SAEs | 9 | Participants | |
| Part A: Maximum Concentration (Cmax) of Voxelotor in Plasma | Part A: Participants Aged 12 to 17 Years: Voxelotor 600 mg | 1880 | Geometric Coefficient of Variation 32.49 | Nanogram per milliliter | |
| Part A: Maximum Concentration (Cmax) of Voxelotor in Plasma | Part A: Participants Aged 6 to 11 Years: Voxelotor 600 mg | 3390 | Geometric Coefficient of Variation 37.82 | Nanogram per milliliter |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02850406/results